FAR Biotech joins JLABS

, /PRNewswire/ -- FAR Biotech, LLC ("FAR Biotech" or "FAR") is pleased to announce that it is now a resident company of Johnson & Johnson's global incubator network, JLABS ("JLABS").

JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, and health tech bring healthcare solutions to patients and consumers.

More information: https://jlabs.jnjinnovation.com/

Dr Martin Martinov, Founder & CEO of FAR Biotech, commented, "We are excited to join the JLABS global network. We believe this further validates our unique QuantumAI approach to drug discovery and our promise to identify novel small molecules for hard-to-drug targets with high unmet need. We greatly look forward to participating and contributing to the JLABS ecosystem network."

About FAR Biotech:  FAR Biotech is a computational drug discovery company that focuses on hard-to-drug targets that are scientifically and commercially attractive due to high unmet need. FAR's unique and proprietary QuantumAI technology can identify novel, structurally diverse, optimized, small molecules that other approaches would not look for, let alone find.

QuantumAI's key differentiator is the complete and rigorous application of Quantum Mechanics, augmented by AI, big data and cheminformatics. Why Quantum Mechanics? Because Quantum Mechanics is the fundamentally correct, physical theory that describes the interaction between drugs and diseases.

FAR's QuantumAI technology has been validated preclinically across a number of therapeutic areas, including oncology, neurodegeneration and infectious diseases.

More information: http://www.farbiotech.com

CONTACT: [email protected]

SOURCE FAR Biotech Inc.